Opthea Ltd. ADR (OPT) News
Filter OPT News Items
OPT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OPT News Highlights
- OPT's 30 day story count now stands at 5.
- Over the past 17 days, the trend for OPT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- TM are the most mentioned tickers in articles about OPT.
Latest OPT News From Around the Web
Below are the latest news stories about OPTHEA LTD that investors may wish to consider to help them evaluate OPT as an investment opportunity.
Optiva and lifecell Named as a Nominee in TM Forum's 16th Annual Excellence AwardsOptiva Inc. ("Optiva" or the "Company") (TSX: OPT), a leader in providing communications service providers (CSPs) worldwide with cloud-native revenue management software on the private and public cloud, is proud to announce that it was selected as a nominee for TM Forum's 16th Excellence Awards 2023. Optiva and lifecell are recognized in the Excellence in Serving People & Planet category for their project "Supporting connectivity, the lifeblood of daily life, with expanded protection in dangerou |
Opthea to Present at the Jefferies 2023 Healthcare ConferenceMELBOURNE, Australia, May 25, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Executive Officer will present at the Jefferies Healthcare Conference being held at the Marriott Marquis in New York City on June 7-9 2023. Dr. Baldwin will present on Wednesday, June 7th at 2:00 – 2:25 PM EST (4:00 A |
Opthea Limited's (ASX:OPT) largest shareholders are individual investors with 40% ownership, institutions own 28%Key Insights The considerable ownership by individual investors in Opthea indicates that they collectively have a... |
Opthea to Participate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD MarketMELBOURNE, Australia, May 17, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Elemer Piros, Senior Biotechnlogy Analyst at EF Hutton will host a webinar with Dr. Megan Baldwin, CEO and Managing Director and Timothy E. Morris, CFO of Opthea Limited on Thursday, May 18th at 5:00 pm EDT (Friday, May 19th at 7:00 am AEST). Participates |
Opthea To Present at the JMP Securities Life Sciences ConferenceMELBOURNE, Australia, May 08, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Timothy E. Morris, the Company’s Chief Financial Officer will present at the JMP Securities Life Sciences Conference being held in New York City on May 15-16 2023. Mr.Morris will present on Tuesday, May 16th at 1:00 pm ET (3:00 am May 17th AEDT), which can |
Opthea To Participate at the H.C. Wainwright BioConnect Conference at NASDAQMELBOURNE, Australia, April 28, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that management will participate in the one-on-one meeting portion of the H.C. Wainwright BioConnect Conference being held on May 2, 2023. The Conference is produced in partnership with NASDAQ and will take place at the exchange’s world headquarters in New Yo |
Opthea Receives A$8.7 million R&D Tax IncentiveMELBOURNE, Australia, March 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that it has received an A$8.7 million (US$6.3 million) research and development (R&D) tax credit from the Australian Taxation Office. The cash incentive is for research and development costs incurred in the 2021/2022 financial year, and represents the amount |
Opthea To Participate in Fireside Chat at Oppenheimer’s 33rd Annual Healthcare ConferenceMELBOURNE, Australia, March 06, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Executive Officer, will participate in a fireside chat at Oppenheimer’s 33rd Annual Healthcare Conference being held virtually on March 13-15, 2023. Dr. Baldwin’s conversation with Hartaj Singh, Managing Director an |
Opthea First Half 2023 Earnings: US$0.17 loss per share (vs US$0.11 loss in 1H 2022)Opthea ( ASX:OPT ) First Half 2023 Results Key Financial Results Net loss: US$77.1m (loss widened by 104% from 1H... |
Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal OphthalmologyMELBOURNE, Australia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that the Phase 2b study results of OPT-302, the Company’s anti-VEGF-C/-D “trap” agent administered in combination with Lucentis® (ranibizumab) for the treatment of wet age-related macular degeneration (AMD), have been published online in Ophthalmology, the jou |